In addition, analysis of recurrent biopsy samples from four patients with metastatic melanoma treated with Ant-PD-1 revealed a truncated mutation in the gene of antigen presentation protein β2-microglobulin (B2M). This evidence concerns the gene PDCD1 and metastatic melanoma.